BS_EVCAC3NH
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- overall_survival_months
- 9.84
- os_event
- false
- age_years
- 3.504
- sex
- F
- e1_e2
- E1
- umap1_2d
- -3.767909181
- umap2_2d
- 2.731771405
- umap1_3d
- -1.515986453
- umap2_3d
- 2.915505797
- umap3_3d
- -1.734926431
- dataset
- EPN-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.500
- PROTEIN_SECRETION+0.400
- MYC_TARGETS_V1+0.390
- HEDGEHOG_SIGNALING+0.330
- MITOTIC_SPINDLE+0.320
- ANGIOGENESIS+0.250
- SPERMATOGENESIS+0.250
- MTORC1_SIGNALING+0.230
- UV_RESPONSE_DN+0.210
Top 10 suppressed
- MYC_TARGETS_V2-0.400
- MYOGENESIS-0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
- INTERFERON_ALPHA_RESPONSE-0.290
- COAGULATION-0.270
- INTERFERON_GAMMA_RESPONSE-0.230
- XENOBIOTIC_METABOLISM-0.180
- IL6_JAK_STAT3_SIGNALING-0.160
- ALLOGRAFT_REJECTION-0.140
- HEME_METABOLISM-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_EVCAC3NH | Supratentorial Ependymoma | — | 0.897 |
| 2 | ERR2598214 | fetal | fetal | 0.760 |
| 3 | 65460 | EPN | Supratentorial EPN | 0.746 |
| 4 | TCGA-96-7544-01A-11R-2045-07 | — | cohortSQ1 | 0.738 |
| 5 | MNG612 | — | — | 0.719 |
| 6 | SRR934977 | — | — | 0.712 |
| 7 | TCGA-77-7142-01A-11R-2045-07 | — | cohortSQ2 | 0.709 |
| 8 | MNG1179 | — | — | 0.684 |
| 9 | MNG727 | — | — | 0.683 |
| 10 | TCGA-BH-A1FM-01A-11R-A13Q-07 | — | B | 0.676 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.160 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.140 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| HYPOXIA | 0.080 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.070 | Cobimetinib | — uncovered |
| APOPTOSIS | 0.050 | Idelalisib | — uncovered |